No Data
No Data
Codexis (CDXS) Gets a Buy From Craig-Hallum
Codexis Successfully Synthesizes An Oligonucleotide Via An Enzymatic Route To Support RNA-Based Therapeutics Manufacturing
Codexis Successfully Synthesizes An Oligonucleotide Via An Enzymatic Route To Support RNA-Based Therapeutics Manufacturing
Codexis Presents Groundbreaking Enzymatic Synthesis Data at TIDES USA Annual Meeting
REDWOOD CITY, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company, today announced it has successfully synthesized an oligonucleotide via an enzymatic route to
Is Codexis (NASDAQ:CDXS) Using Too Much Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' So it seems the smart money knows that debt - which is usu
Codexis First Quarter 2024 Earnings: Beats Expectations
Benchmark Reiterates Buy on Codexis, Maintains $9 Price Target
Benchmark analyst Robert Wasserman reiterates Codexis (NASDAQ:CDXS) with a Buy and maintains $9 price target.
No Data